Recursion Pharmaceuticals, Inc. RXRX Business Sale Proceeds
Business Sale Proceeds at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s business sale proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s business sale proceeds?
- Recursion Pharmaceuticals, Inc. (RXRX) reported business sale proceeds of $0 in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s business sale proceeds changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s business sale proceeds increased by 100.0% year-over-year, from -$4.44M to $0.
- What does business sale proceeds mean?
- Cash received from divesting business units or subsidiaries, net of cash in the disposed entity.